throbber
Dr. Reddy’s Laboratories, Inc. v. Celgene Corp.
`IPR2018-01509
`Exhibit 2033, Page 1
`
`

`

`Dr. Reddy’s Laboratories, Inc. v. Celgene Corp.
`0
`
`Exhibit 2033, Page 2
`
`

`

` || ' iffft
`
`i symbol for 1 iso (def. 3): (as a prefix or superscript in symbols
`and abbreviations for iso compounds or groups; c.g. isopropyl
`can be symbolized as iPr or Pr’). 2 the chemical group 2-
`isopentenyl!; 3,3-dimethylally! (as a prefix to a single-letter
`symbol for a nucleoside residue to designate substitution of
`the base, as in iA). 3 the square root of ~1.
`isymbolfor 1 electric current (alternative to /). 2 van't Hoff fac-
`tor.
`I symbol for 1 iodine. 2 an iodo group in an organic compound.
`3 a residue of the @-aminoacid L-isoleucine (alternative to
`lie). 4 a residue of the ribonucleoside inosine (alternative to
`Ino).
`I symbol for 1 electric current (preferred alternative to1). 2 in-
`tensity; the subscripts e (for energetic), p (for photon), or v
`(for visible) may be added to distinguish between radiant in-
`tensity, photon intensity, and luminous intensity, respectively.
`3 ionic strength; the subscripts ¢ or m may be added to indi-
`cate whether it is expressed based on concentration or molal-
`ity respectively. 4 the inductive effect of a particular chemical
`group in an organic compound.
`iA symbolfor N®-(2-isopentenyl)adenosine, a hypermodified base.
`IAA abbr. for indole-3-acetic acid or indoleacetate.
`IAN abbr. for indoleacetonitrile.
`IAP abbr. for islet-activating protein; sce pertussis toxin.
`iatrogenic describing a condition or disease induced uninten-
`tionally by a physician through his or her diagnosis, manner,
`or therapy. —iatrogenicity 7.
`I-band abbr.for isotropic band. The I-bandsofstriated muscle
`contain the thin filaments and correspond to the light bands.
`The name derives from the fact that they are isotropic in po-
`larized light. See also sarcomere.
`IBMX abbr. for isobutylmethylxanthine.
`ibuprofen 2-(4-isobutylphenyl)propionic acid: a nonsteroidal
`anti-inflammatory agent of the substituted propionic acid
`type; others of this type are flurbiprofen, ketoprofen. and
`naproxen. They inhibit the cyclooxygenase activity of prosta-
`glandin-endoperoxide synthase, reversibly over short time inter-
`vals, followed by time-dependent irreversible inactivation, duc
`probably to conformational rather than covalent changes. The
`racemic mixture is present
`in many over-the-counter drugs,
`but the (S)-enantiomer is the active form. Proprietary names
`include: Advil: Brufen: Motrin.
`
`
`
`| a
`
`kDa, are expressed on B and Tcells, endothelial, epithelial,
`and dendritic cells. fibroblasts. keratinocytes, and chondro-
`cytes. They are inducible in 12-24 hours by cytokines such as
`gammainterferon. interleukin-1B, and tumour necrosis factor-
`a. Example (human, precursors):
`ICAM-1 major group rhi-
`novirus receptor: database code ICA]. HUMAN, 532 amino
`acids (57.76 kDa). ICAM-2 (er CD102), of molecular mass
`55-65 kDa, are constitutively expressed on endothelial cells.
`some lymphocytes, monocytes, and dendritic cells. Example
`(human): database code ICA2,_ HUMAN, 275 amino acids
`(30.62 kDa). ICAM-3 (vr CD50), of molecular mass 116-140
`kDa, are constitutively expressed on monocytes, granulocytes.
`and lymphocytes; upon physiological stimulation they become
`rapidly and transiently phosphorylated on serine residues. Ex-
`ample (human): database code ICA3_HUMAN, 547 amino
`acids (59.32 kDa).
`§CD (in clinical chemistry) abbr. for isocitrate dehydrogenase
`(EC1.1.1.41).
`ice the solid formof water that can exist at temperatures below
`the triple point of water (273.16 K at 101 325 Pa).
`iceberg a metaphor used to describe an interpretation of the
`anomalousentropiesof solution of noble gases and other non-
`polar substances in water, suggesting that water tends to organ-
`ize itself into quasi-solid supramolecular structures aroundthe
`molecules of such substances. In the case of alkyl compounds.
`this tendency increases markedly with the length of the alkyl
`chain.
`ICE-like protease any of a family of endopeptidases that
`structurally resemble interleukin-1B convertase (ICE). They are
`involved in apoptosis, being implicated in the proteolysis that
`causes cell death.
`Icell
`1 or CCK cell anyof a group ofcells, widely distributed
`in the duodenal and jejunal mucosa, that produce cholecysto-
`kinin. So named because their histological features are inter-
`mediate between those of $ cells and L cells. 2 abbr. for
`inclusion cell, See also |-cell disease.
`[-cell disease or inclusion-cell disease vr mucolipidosis I] an
`autosomal recessive disease in which most of the lysosomes in
`the connective tissue (fibroblasts) contain large inclusions of
`glycoaminoglycans and glycolipids as a result of the absence
`of several
`lysosomal hydrolases. These enzymes, which are
`synthesized in the endoplasmic reticulum, are secreted into the
`extracellular medium rather than being directed to the lyso-
`somes. This is due to the absence of a mannose 6-phosphate
`marker on the carbohydrate moieties of these hydrolases be-
`cause of a deficiency in an enzyme required for mannose phos-
`phorylation. The failure of the phosphorylation in the cis
`Golgi network means that the enzymes are not segregated by
`the mannose 6-phosphate receptors into the appropriate transport
`vesicles in the trans Golgi network. The patients have an ab-
`normally high level of lysosomal enzymes in their sera and
`bodyfluids. A milder form of I-cell disease is Hurler’s poly-
`dystrophy (Hurler syndrome).
`for intracutaneous or intracutaneously.
`ic or i.c. abbr.
`ice point the temperature at which ice melts. It is taken as the
`IC abbr. for internal conversion
`temperature (273.15 K) at which ice and water are in equilib-
`ICgq 1 the median inhibitory concentration (in mo] L ') of an
`riumat standard pressure (101 325 Pa). It was used as a reter-
`antagonist, i.e. the concentration that reduces a specified re-
`ence temperature on the Celsius scale. but the kelvin is based
`sponse to 50%ofits former value: compare ECypy. 2 the median
`instead on the temperature at thetriple point of water (273.16 K).
`inhibitory concentration (in mol L-') of an agent (agonist or
`antagonist), i.e. the concentration that causes a 50% reduction CF abbr. for intracellular fluid.
`ichthyotocin an alternative name forisotocin.
`in the specific binding of a radioligand.
`ICAM abbr. for intercellular adhesion molecule: any of several
`icosa+ or (before a vowel) icos+ comb, form recommended for
`denoting twenty or twenty times. Also (formerly): eicosat.
`type | membrane glycoproteins of the immunoglobulin super-
`eicos+. (Note: the eicos(a)+ variant is still always used for the
`family. They act as ligands for leukocyte adhesion to target
`Crp fatty acids and skeletally related compounds, e.g.
`the
`cells,
`in conjunction with LFA-1;
`in fact LFA-!-ICAMlinks
`eicosanoids.)
`mediate adhesion between many cell
`types. There are three
`subclasses.
`ICAM-I
`(or CD54), of molecular mass 90-115
`icosadeltahedron (p/. icosadeltahedra) any solid geometrical
`
` H3C
`
`(S)-ibuprofen
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket